Ambry Genetics Introduces AmbryScreen™ - A Genetic Test Screening for Newborns
News May 20, 2010
Ambry Genetics has announced at the American College of Obstetricians and Gynecologists annual clinical meeting the launch of AmbryScreen™, a genetic screening test used to identify carriers of some of the most severe and common childhood diseases affecting pan-ethnic populations.
Designed by a team of geneticists and genetic counselors with decades of clinical and laboratory experience, the panel is a responsible and ethical means of identifying individuals at high risks to have a child with severe genetic conditions. As with all clinical assays performed by Ambry Genetics, the test must be ordered by a physician. It is not available direct to consumer.
The AmbryScreen™ test screens for over 90 childhood onset conditions representing only severe or common diseases. The core of the AmbryScreen™ test is the most sensitive Cystic Fibrosis carrier mutation panel in the marketplace. It was designed by coupling the public databases of information along with Ambry's extensive database of over 25,000 patients sequenced in the last decade. Our 100 CF mutation panel includes only well defined disease causing mutations, without containing mild CF mutations like some competing tests.
"With more direct to consumer type tests coming online, we want to clearly differentiate ourselves from those laboratories. We have the experience, the compliance to regulatory guidelines and laws, and the professional staff and expertise to handle these types of tests adequately." Taosheng Huang MD, PhD, FACMG, Medical Director.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE